利伐沙班如何使用？

Rivaroxaban is a drug that prevents venous thrombosis. So, how is rivaroxaban used?

How to use rivaroxaban:

Under normal circumstances, the usual dosage is 10 mg once a day. If the wound has stopped bleeding, the first dose of medication should be given between 6-12 hours after the operation, which can have an anticoagulant effect and prevent blood clots.

For use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism

The recommended dose is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

In situations where the benefits of rivaroxaban in preventing stroke and systemic embolism outweigh the risks of bleeding, long-term treatment should be considered.

If a missed dose occurs, the patient should take rivaroxaban immediately and continue receiving the once-daily dose the next day. The dose should not be doubled in one day to make up for a missed dose.

Discontinuation of medication due to surgery and other interventional treatments

If anticoagulant therapy must be discontinued to reduce the risk of bleeding during surgery or other intervention, rivaroxaban must be discontinued at least 24 hours before the intervention to reduce the risk of bleeding. Given the rapid onset of action of rivaroxaban, rivaroxaban should be reintroduced as soon as adequate hemostasis is determined after surgery or other interventional procedures. If oral medications cannot be taken during or after surgical intervention, consider administering a non-oral anticoagulant.

Dosing options

For patients who cannot swallow the whole tablet, crush the 10 mg, 15 mg or 20 mg rivaroxaban tablet before taking the medicine, mix it with applesauce and take it immediately. Food should be eaten immediately after administration of crushed rivaroxaban 15 mg or 20 mg tablets.

Switching from a vitamin K antagonist (VKA) to rivaroxaban

In patients with reduced risk of stroke and systemic embolism, VKA should be discontinued and rivaroxaban treatment should be initiated when the international normalized ratio (INR) is ≤3.0.

For patients who want to treat DVT and reduce the risk of DVT recurrence and PE after acute DVT, VKA should be discontinued and rivaroxaban treatment should be initiated when the international normalized ratio (INR) is ≤2.5.